Phytosterols: From Preclinical Evidence to Potential Clinical Applications

Bahare Salehi(Shahid Beheshti University of Medical Sciences), Cristina Quispe(Arturo Prat University), Javad Sharifi‐Rad(Universidad del Azuay), Natália Martins(Universidade do Porto), Manisha Nigam(Hemwati Nandan Bahuguna Garhwal University), Abhay Prakash Mishra(Shobhit University), Д. А. Коновалов(Volgograd State Medical University), Valeriya Orobinskaya(North-Caucasus Federal University), Ibrahim M. Abu‐Reidah(Memorial University of Newfoundland), Wissam Zam(Al Andalus University), Farukh Sharopov(Academy of Sciences of the Republic of Tajikistan), Tommaso Venneri(University of Naples Federico II), Raffaele Capasso(Federico II University Hospital), Wirginia Kukuła‐Koch(Medical University of Lublin), Anna Wawruszak(Medical University of Lublin), Wojciech Koch(Medical University of Lublin)
Frontiers in Pharmacology
January 14, 2021
Cited by 279Open Access
Full Text

Abstract

Phytosterols (PSs) are plant-originated steroids. Over 250 PSs have been isolated, and each plant species contains a characteristic phytosterol composition. A wide number of studies have reported remarkable pharmacological effects of PSs, acting as chemopreventive, anti-inflammatory, antioxidant, antidiabetic, and antiatherosclerotic agents. However, PS bioavailability is a key issue, as it can be influenced by several factors (type, source, processing, preparation, delivery method, food matrix, dose, time of administration into the body, and genetic factors), and the existence of a close relationship between their chemical structures (e.g., saturation degree and side-chain length) and low absorption rates has been stated. In this sense, the present review intends to provide in-depth data on PS therapeutic potential for human health, also emphasizing their preclinical effects and bioavailability-related issues.


Related Papers

No related papers found

Powered by citation graph analysis